Literature DB >> 6145035

Self-administered home intravenous antibiotic therapy in bronchiectasis and adult cystic fibrosis.

R J Winter, R J George, S J Deacock, C D Shee, D M Geddes.   

Abstract

10 patients (mean age 23.1, range 17.1-40.5 years), 8 with cystic fibrosis (CF), and 2 with advanced bronchiectasis without CF, were taught, while being treated in hospital for exacerbations of pseudomonas infection, how to continue to give themselves intravenous antibiotics at home. They were discharged after satisfactory antibiotic levels had been achieved, and 22 courses were given at home over a total of 116 patient-days. In 14 of these, the greater part of the course was given at home (mean duration 6.6, range 5-10 days); 2 of these were given without admission to hospital. In the 8 patients with two or more infective exacerbations within a 12-month period there was no difference between home and hospital treatments in clinical improvement or in relapse time, defined as the interval between completion of treatment and subsequent antibiotic therapy. Self-administration of antibiotics intravenously at home for selected adults with cystic fibrosis and severe bronchiectasis reduces hospital stay and does not seem to be associated with an increased rate of recurrent infection.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6145035     DOI: 10.1016/s0140-6736(84)91829-4

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  11 in total

1.  Community-based parenteral anti-infective therapy (CoPAT). Pharmacokinetic and monitoring issues.

Authors:  D N Williams; J L Raymond
Journal:  Clin Pharmacokinet       Date:  1998-07       Impact factor: 6.447

2.  Home intravenous anti-infective therapy (HIVAT): do the benefits outweigh the risks?

Authors:  D N Williams
Journal:  Drug Saf       Date:  1996-01       Impact factor: 5.606

3.  An audit of the effect of intravenous antibiotic treatment on spirometric measures of pulmonary function in cystic fibrosis.

Authors:  J M Bradley; E S Wallace; J S Elborn; J L Howard; M P McCoy
Journal:  Ir J Med Sci       Date:  1999 Jan-Mar       Impact factor: 1.568

4.  [Cost comparison of hospital and ambulatory i.v. therapy in adult cystic fibrosis patients. Results of a controlled prospective study].

Authors:  C Krauth; R Busse; C Smaczny; G Ullrich; T O Wagner; J Weber; T Welte
Journal:  Med Klin (Munich)       Date:  1999-10-15

Review 5.  Cystic fibrosis: cost of illness and considerations for the economic evaluation of potential therapies.

Authors:  Christian Krauth; Noushin Jalilvand; Tobias Welte; Reinhard Busse
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

Review 6.  Quality of life in children and adolescents with cystic fibrosis: implications for optimizing treatments and clinical trial design.

Authors:  Janice Abbott; Louise Gee
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

7.  Home intravenous antibiotic therapy in children with cystic fibrosis: clinical outcome, quality of life and economic benefit.

Authors:  E A Chrysochoou; E Hatziagorou; F Kirvassilis; J Tsanakas
Journal:  Hippokratia       Date:  2016 Oct-Dec       Impact factor: 0.471

8.  Home intravenous antibiotic treatment in cystic fibrosis.

Authors:  J Gilbert; T Robinson; J M Littlewood
Journal:  Arch Dis Child       Date:  1988-05       Impact factor: 3.791

9.  Long term clinical outcome of home and hospital intravenous antibiotic treatment in adults with cystic fibrosis.

Authors:  J Thornton; R Elliott; M P Tully; M Dodd; A K Webb
Journal:  Thorax       Date:  2004-03       Impact factor: 9.139

10.  Home intravenous antibiotic treatment for acute pulmonary exacerbations in cystic fibrosis - Is it good for the patient?

Authors:  Iara Maria Sequeiros; Nabil A Jarad
Journal:  Ann Thorac Med       Date:  2009-07       Impact factor: 2.219

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.